Antileishmanial Effect of Silver Nanoparticles and Their Enhanced Antiparasitic Activity Under Ultraviolet Light

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2011 Nov 25

PMID 22114501

Citations 65

Authors

Adil M Allahverdiyev

Emrah Sefik Abamor

Malahat Bagirova

Cem B Ustundag

Cengiz Kaya

Figen Kaya

Miriam Rafailovich

Affiliations

Soon will be listed here.

Abstract

Leishmaniasis is a protozoan vector-borne disease and is one of the biggest health problems of the world. Antileishmanial drugs have disadvantages such as toxicity and the recent development of resistance. One of the best-known mechanisms of the antibacterial effects of silver nanoparticles (Ag-NPs) is the production of reactive oxygen species to which Leishmania parasites are very sensitive. So far no information about the effects of Ag-NPs on Leishmania tropica parasites, the causative agent of leishmaniasis, exists in the literature. The aim of this study was to investigate the effects of Ag-NPs on biological parameters of L. tropica such as morphology, metabolic activity, proliferation, infectivity, and survival in host cells, in vitro. Consequently, parasite morphology and infectivity were impaired in comparison with the control. Also, enhanced effects of Ag-NPs were demonstrated on the morphology and infectivity of parasites under ultraviolet (UV) light. Ag-NPs demonstrated significant antileishmanial effects by inhibiting the proliferation and metabolic activity of promastigotes by 1.5- to threefold, respectively, in the dark, and 2- to 6.5-fold, respectively, under UV light. Of note, Ag-NPs inhibited the survival of amastigotes in host cells, and this effect was more significant in the presence of UV light. Thus, for the first time the antileishmanial effects of Ag-NPs on L. tropica parasites were demonstrated along with the enhanced antimicrobial activity of Ag-NPs under UV light. Determination of the antileishmanial effects of Ag-NPs is very important for the further development of new compounds containing nanoparticles in leishmaniasis treatment.

Citing Articles

Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.

Zhang H, Yan R, Liu Y, Yu M, He Z, Xiao J PLoS Negl Trop Dis. 2025; 19(1):e0012735.

PMID: 39752369 PMC: 11698350. DOI: 10.1371/journal.pntd.0012735.

Goethite and Hematite Nanoparticles Show Promising Anti-Toxoplasma Properties.

Ishii K, Akahoshi E, Adeyemi O, Bando H, Fukuda Y, Ogawa T Pharmaceutics. 2024; 16(3).

PMID: 38543307 PMC: 10974022. DOI: 10.3390/pharmaceutics16030413.

Green Synthesis of Uncoated and Olive Leaf Extract-Coated Silver Nanoparticles: Sunlight Photocatalytic, Antiparasitic, and Antifungal Activities.

Alotaibi N, Alqarni L, Alghamdi S, Al-Ghamdi S, Amna T, Alzahrani S Int J Mol Sci. 2024; 25(6).

PMID: 38542055 PMC: 10970606. DOI: 10.3390/ijms25063082.

Use of nanoparticles, a modern means of drug delivery, against cryptosporidiosis.

AlFaleh F, Ismael S, Aguilar-Marcelino L, Silva F, Ashraf T, Abbas R J Adv Vet Anim Res. 2024; 10(4):704-719.

PMID: 38370897 PMC: 10868694. DOI: 10.5455/javar.2023.j726.

Green synthesis of silver and iron oxide nanoparticles mediated photothermal effects on Blastocystis hominis.

Alexeree S, Abou-Seri H, El-Din H, Youssef D, Ramadan M Lasers Med Sci. 2024; 39(1):43.

PMID: 38246979 PMC: 10800310. DOI: 10.1007/s10103-024-03984-6.

References

Sambhy V, MacBride M, Peterson B, Sen A . Silver bromide nanoparticle/polymer composites: dual action tunable antimicrobial materials. J Am Chem Soc. 2006; 128(30):9798-808. DOI: 10.1021/ja061442z. View

Murray H . Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med. 1981; 153(5):1302-15. PMC: 2186145. DOI: 10.1084/jem.153.5.1302. View

Swai H, Semete B, Kalombo L, Chelule P, Kisich K, Sievers B . Nanomedicine for respiratory diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 1(3):255-63. DOI: 10.1002/wnan.33. View

Tsuang Y, Sun J, Huang Y, Lu C, Chang W, Wang C . Studies of photokilling of bacteria using titanium dioxide nanoparticles. Artif Organs. 2008; 32(2):167-74. DOI: 10.1111/j.1525-1594.2007.00530.x. View

Kim J, Lee C, Cho M, Yoon J . Enhanced inactivation of E. coli and MS-2 phage by silver ions combined with UV-A and visible light irradiation. Water Res. 2007; 42(1-2):356-62. DOI: 10.1016/j.watres.2007.07.024. View

Choi O, Hu Z . Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. Environ Sci Technol. 2008; 42(12):4583-8. DOI: 10.1021/es703238h. View

Chopra I . The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?. J Antimicrob Chemother. 2007; 59(4):587-90. DOI: 10.1093/jac/dkm006. View

Herwaldt B, Berman J . Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992; 46(3):296-306. DOI: 10.4269/ajtmh.1992.46.296. View

Angeli E, Buzio R, Firpo G, Magrassi R, Mussi V, Repetto L . Nanotechnology applications in medicine. Tumori. 2008; 94(2):206-15. DOI: 10.1177/030089160809400213. View

10.

Hemmer C, Frimmel S, Kinzelbach R, Gurtler L, Reisinger E . [Global warming: trailblazer for tropical infections in Germany?]. Dtsch Med Wochenschr. 2007; 132(48):2583-9. DOI: 10.1055/s-2007-993101. View

11.

Zheng J, Wu X, Wang M, Ran D, Xu W, Yang J . Study on the interaction between silver nanoparticles and nucleic acids in the presence of cetyltrimethylammonium bromide and its analytical application. Talanta. 2008; 74(4):526-32. DOI: 10.1016/j.talanta.2007.06.014. View

12.

Sondi I, Salopek-Sondi B . Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci. 2004; 275(1):177-82. DOI: 10.1016/j.jcis.2004.02.012. View

13.

Pal S, Tak Y, Song J . Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol. 2007; 73(6):1712-20. PMC: 1828795. DOI: 10.1128/AEM.02218-06. View

14.

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M . New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis. 2008; 47(8):1000-6. DOI: 10.1086/591972. View

15.

Matsumura Y, Yoshikata K, Kunisaki S, Tsuchido T . Mode of bactericidal action of silver zeolite and its comparison with that of silver nitrate. Appl Environ Microbiol. 2003; 69(7):4278-81. PMC: 165194. DOI: 10.1128/AEM.69.7.4278-4281.2003. View

16.

Russell A, HUGO W . Antimicrobial activity and action of silver. Prog Med Chem. 1994; 31:351-70. DOI: 10.1016/s0079-6468(08)70024-9. View

17.

Croft S . Recent developments in the chemotherapy of leishmaniasis. Trends Pharmacol Sci. 1988; 9(10):376-81. DOI: 10.1016/0165-6147(88)90258-1. View

18.

Liau S, Read D, Pugh W, Furr J, Russell A . Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ions. Lett Appl Microbiol. 1997; 25(4):279-83. DOI: 10.1046/j.1472-765x.1997.00219.x. View

19.

Shrivastava S, Bera T, Roy A, Singh G, Ramachandrarao P, Dash D . Retracted: Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology. 2023; 18(22). DOI: 10.1088/0957-4484/18/22/225103. View

20.

Debbage P . Targeted drugs and nanomedicine: present and future. Curr Pharm Des. 2009; 15(2):153-72. DOI: 10.2174/138161209787002870. View